Dibunate is a cough suppressant.[1] As the sodium salt, it has been marketed under the name Becantyl (in the United Kingdom), Becantex (in continental Europe), or Linctussal with a dosage of 20 to 30 mg, as either syrup or tablets.[2]
Clinical data | |
---|---|
Trade names | Aducin, Becantal, Becantex, Bechisan, Bexedyl, Keuten, Linctussal, Pectoro |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.035.511 |
Chemical and physical data | |
Formula | C18H24O3S |
Molar mass | 320.45 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Similar to benzonatate, it is a peripherally acting drug. It has not been reported to cause sedation, euphoria, habituation, or respiratory depression, unlike narcotic antitussives such as codeine. It may work by blocking afferent signals in the reflex arc which controls cough.[3] Nausea is rarely seen as an adverse effect.[4]
References
edit- ^ Sevelius H, Colmore JP (1967). "Antitussive effect of ethyl dibunate in patients with chronic cough". Clinical Pharmacology and Therapeutics. 8 (3): 381–4. doi:10.1002/cpt196783381. PMID 5338382.
- ^ "To-day's drugs: Cough suppressants". Br Med J. 1 (5391): 1165-1167. May 2, 1964. PMC 1813498. PMID 14120813.
- ^ Simon SW (1957). "A comparative study of two new non-narcotic antitussive drugs". Ohio State Med J. 53 (12): 1426-7. PMID 13493953.
- ^ Schlesser JL (1991). Drugs Available Abroad, 1st Edition. Derwent Publications Ltd. p. 63. ISBN 0-8103-7177-4.